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Introduction: Human amniotic fluid stem (hAFS) cells have been shown to differentiate into multiple lineages,
including myoblasts. However, molecular mechanisms underlying the myogenic differentiation of hAFS cells and
their regenerative potential for muscle injury remain to be elucidated.
Methods: In order to induce myogenic differentiation of hAFS cells, lentiviruses for MYOD were constructed and
transduced into hAFS cells. Formation of myotube-like cells was analyzed by immunocytochemistry, and expression
of molecular markers for myoblasts was analyzed by reverse transcription polymerase chain reaction and Western
blotting. For in vivo muscle regeneration, MYOD transduced hAFS cells were injected into left tibialis anterior
(TA) muscles injured with cardiotoxin, and muscle regeneration was analyzed using hematoxylin and eosin,
immunocytochemistry and formation of neuro-muscular junction.
Results: MYOD expression in hAFS cells successfully induced differentiation into multinucleated myotube-like cells.
Consistently, significant expression of myogenic marker genes, such asMYOG, DES, DMD and MYH, was induced by MYOD.
Analysis of pre-myogenic factors showed that expression of PAX3, MEOX1 and EYA2 was significantly increased
by MYOD. MYOD was phosphorylated and localized in the nucleus. These results suggest that in hAFS cells,
MYOD is phosphorylated and localized in the nucleus, thus inducing expression of myogenic factors, resulting in
myogenic differentiation of hAFS cells. To test regenerative potential of MYOD-transduced hAFS cells, we transplanted them
into injured muscles of immunodeficient BALB/cSlc-nu mice. The results showed a substantial increase in the volume of TA
muscle injected with MYOD-hAFS cells. In addition, TA muscle tissue injected with MYOD-hAFS cells has more numbers of
neuro-muscular junctions compared to controls, indicating functional restoration of muscle injury by MYOD-hAFS cells.
Conclusions: Collectively, our data suggest that transduction of hAFS cells with MYOD lentiviruses induces skeletal
myogenic differentiation in vitro and morphological and functional regeneration of injured muscle in vivo.Introduction
Recently, accumulating evidence has demonstrated the
ability of amniotic fluid stem (AFS) cells to differenti-
ate into multiple lineages [1-4]. Indeed, clonal AFS cells
can produce all three embryonic germ layer-derived
cells, allowing for classification of AFS cells as
broadly multipotent cells [5-7]. Although AFS cells ori-
ginate from embryonic and extra-embryonic tissues [4],
unlike embryonic stem cells, which are obtained from
the inner cell mass of blastocysts, they do not form* Correspondence: epark@knu.ac.kr
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reproduction in any medium, provided the ortumors after implantation in mice [7]. As a consequence,
AFS cells could be a safe and easily available stem cell
source for therapeutic purposes [2,6-8].
AFS cells harbor some of the characteristics of embryonic
stem cells. In particular, AFS cells express the transcription
factor OCT4, which is known to be expressed in embryonic
stem cells. In addition, AFS cells also express the pluripo-
tent stem cell marker, telomerase reverse transcriptase [9].
These results suggest that, in terms of their versatility, AFS
cells have an intermediate potential between embryonic
and adult stem cells [7,9].
Myogenic differentiation of mesenchymal stem cells
(MSCs) can be induced by DNA demethylation, co-culture
with myoblasts, or in vivo muscle engraftment [10-15].. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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master gene for myogenesis. MYOD is expressed at an
early stage of myogenic differentiation, which, in turn,
induces expression of other myogenesis-related genes,
such as myogenin. In physiological conditions, MYOD can
be phosphorylated or dephosphorylated. The phosphory-
lated form inhibits the DNA binding activity of MYOD
homodimer, but does not affect DNA binding of MYOD-
E12 heterodimers [16]. The dephosphorylated form of
MYOD causes cell fusion under conditions of high mito-
genesis [17]. During myogenesis of human adipocyte de-
rived mesenchymal stem cells, phosphorylation of MYOD
is increased at five days, and then shows a decrease over
14 days [18]. Translocation of MYOD from the cytosol to
the nucleus is also regulated by phosphorylation [19].
Therefore, the activity and translocation of MYOD can be
regulated primarily by phosphorylation. Recent studies have
reported that overexpression of key transcription factors
in developmental myogenesis, such as MYOD [20-22]
and PAX3 [23], induces myogenic differentiation in MSCs.
However, in human AFS (hAFS) cells, the molecular mech-
anism of MYOD-induced myogenesis is not understood.
In this study, we demonstrate that expression of MYOD
with a lentiviral system in hAFS cells induces formation of
multinucleated myotubes. MYOD induces pre-myogenic
gene expression, followed by expression of skeletal
myogenic markers in hAFS cells. We also show that hAFS
expressing MYOD can significantly promote in vivo muscle
regeneration.
Methods
Isolation and characterization of hAFS cells
Human amniotic fluid (16 to 18 weeks of gestation) was
obtained from donors at Kyungpook National University
Hospital who provided informed consent. The amniotic
fluid was transferred to the Joint Institute for Regenerative
Medicine (JIRM): Kyungpook National University Hospital-
Wake Forest Institute for Regenerative Medicine for isola-
tion of hAFS cells. Isolation of hAFS cells and experimental
procedures were approved by the Institutional Research
Board of Kyungpook National University Hospital (KNUH-
BIO_09-1008). Briefly, amniotic fluid was centrifuged and
cultured in (D)MEM high-glucose containing 10% FBS,
and 1% penicillin/streptomycin (Invitrogen, Carlsbad, CA,
USA) for one week, as previously described [7]. For
maintenance of human AFS cells, the cells were cultured in
α-MEM medium containing 15% ES-FBS, 1% glutamine,
and 1% penicillin/streptomycin (Invitrogen), supplemented
with 18% Chang B and 2% Chang C (Irvine Scientific,
Santa Ana, CA, USA) at 37°C in a 5% CO2 atmosphere.
Confluent hAFS cells were harvested by trypsinization for
further expansion.
Expression of pluripotent markers was identified by
RT-PCR using specific primers for OCT4, SCF, GATA4,VIM, CK18 and FGF5. Cell surface mesenchymal stem
cell markers such as CD44, CD73, CD90 and CD105 were
analyzed using flow cytometry (FACS Aria, BD bioscience,
San Jose, CA, USA), as described previously [24]. PE-
conjugated primary antibodies were obtained from BD
bioscience.
Preparation of lentiviruses and transduction
The human MYOD or empty DNA vector was inserted
into the lentiviral vector pHJ-1. To make the virus par-
ticle solution, human MYOD or empty pHJ-1 lentiviral
vector was co-transfected with lentiviral packaging vectors
(pHDM-Hgpm2, pRC/CMV-Rev1b, and pHDM.G) into
6 × 104 cells/cm2 293FT cells. The culture supernatant
was collected 48 hours later and centrifuged for removal
of 293FT cells and debris. They were frozen for storage
in a deep-freezer. Lentivirus supernatant was thawed with
water at room temperature and mixed with an equal vol-
ume of culture media. For lentiviral transduction, the viral
supernatants were added to 6 × 103 cells/cm2 hAFS cells
in the presence of 8 μg/ml polybrene for 12 hours. After
12 hours, the cells were washed with PBS and changed
with fresh culture media. First, hAFS cells were infected
with eGFP lentivirus, and approximately more than 80%
of the hAFS cells were eGFP-positive. The infected cells
were then sorted using FACS Aria. The eGFP-positive
hAFS cells were cultured for three days and then trans-
duced again with MyoD or EV lentivirus. During this
time period, the cells did not show any sign of cell death
(data not shown).
Reverse transcription PCR
Total RNA was extracted from cultured hAFS cells using
Tri-solution (Bioscience, Gyeongsan, Korea). First-strand
complementary DNA was synthesized with 1 μg total RNA
using the Super Script II First-Strand Synthesis System
(Invitrogen). From the 20 μl complementary DNA reaction
volume, 1 to 2 μl were used for each PCR assay. The
primers used in this study were as follows: MYH: forward,
5′-TGTGAATGCCAAATGTGCTT -3′, and reverse, 5′-G
CCTTTATTTTGATCACC-3′; MYOG: forward, 5′-CAG
CGAATGCAGCTCTCACA-3′, and reverse, 5′-AGTTGG
GCATGGTTTCATCTG-3′; MYOD: forward, 5′-AGCAC
TACAGCGGCGACT-3′, and reverse, 5′-GCGACTCAGA
AGGCACGTC-3′; DES: forward, 5′-CCTAC TCTGCCC
TCAACTTC-3′, and reverse, 5′-AGTATCCCAACACCC
TGCTC-3′; and MEF2C: forward, 5′-GGGTGGAGACC
TCACGTCTG-3′, and reverse, 5′-TTATTTATCCTTTGA
TTCA CTGATG-3′. PAX3: forward, 5′-GTCAACCAGCT
CGGCGGTGTTT-3′, and reverse, 5′-ATGGCACCAGGA
CGTATGGGT-3′, MEOX1: forward, 5′-AAAGGACCGA
GGCGTGCAGC-3′, and reverse, 5′-CTCCTCCTGGGG
CAGGCTGT-3′, SIX1: forward, 5′-CTTAAAGGCTACT
GAGTGCGCCG-3′, and reverse, 5′-TGCGTAAAGCCAA
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GGACTCTGAGT-3′, and reverse, 5′-AGTGGGTGA GG
TGCTGAAGGAAGGG-3′, GLI2: forward, 5′-TGGAATT
TGGAACTGGCTTC-3′, and reverse, 5′-CCTCATTAAG
GCC AAGGTC A-3′, FOXC1: forward, 5′-AGGAAGGCG
AGAGGAGCAGAACAT -3′, and reverse, 5′-GATTGGC
AGGGCAGATCACCC-3′, FOXC2: forward, 5′-TCCACG
CCGCCTCTCTATCGC-3′, and reverse, 5′-TTGCGTCTC
TGCAGCCCCTTAAT-3′. A primer set of the housekeep-
ing gene GAPDH was used as an internal control. Comple-
mentary DNA was amplified using a LA Taq™ polymerase
with GC buffer (Takara, Tokyo, Japan) with a total of 25
to 40 cycles. PCR products were resolved by agarose gel
electrophoresis.Western blotting
hAFS cells were detached physically from culture dishes
using a cell scrapper and sonicated in RIPA buffer (50 mM
Tris–HCl pH 8.0, 150 mM NaCl, 1% NP-40, 0.5% sodium
deoxycholate, 0.1% sodium dodecyl sulfate (SDS)). Protein
concentration was determined using a BCA protein assay
kit (Interchim, Montlucon, France). Protein samples were
separated in SDS-PAGE and transferred to Protran
membranes (Whatman, Florham Park, NJ, USA). The
membrane was blocked with 3% non-fat dry milk in
TBS-T and each primary and corresponding secondary
antibody was incubated for one hour. Primary antibodies
and dilutions used were as follows: mouse monoclonal
anti-MyoD (BD biosciences) at 1:500; rabbit polyclonal
anti-Myf5 (C-20) (Santa Cruz Biotechnology, Inc. Dallas,
TX, USA) at 1:200; mouse monoclonal anti-desmin
(BD biosciences) at 1:500; rabbit polyclonal anti-dystrophin
(Abcam Inc., Cambridge, MA) at 1:200 and mouse
monoclonal anti-FLAG M2 (Sigma-Aldrich Co. St.
Louis, MO, USA). Secondary antibodies conjugated to
horseradish peroxidase (HRP) were obtained from Invi-
trogen. The signal was detected using WesternBright
ECL (Advensta, Menlo Park, CA, USA).
Nucleus and cytoplasm were fractionated as described
previously [25]. Briefly, collected cells were re-suspended
with buffer A (10 mM HEPES pH 7.9, 1.5 mM MgCl2,
10 mM KCl, 0.5 mM dithiothreitol (DTT), 0.05% NP40),
placed on ice for 10 minutes and centrifuged at 4°C at
3,000 rpm for 10 minutes. Supernatant was kept as a
cytoplasmic fraction. The pellets were resuspended in
374 μl of buffer B (5 mM HEPES pH 7.9, 1.5 mM MgCl2,
0.2 mM ethylenediaminetetraacetic acid (EDTA), 0.5 mM
DTT, 26% (v/v) glycerol) and 26 μl of 4.6 M NaCl (300
mM NaCl). The re-suspended pellets were homogenized
with full strokes in a Dounce or glass homogenizer and
placed on ice for 30 minutes, followed by centrifugation
(14,000 rpm) at 4°C for 30 minutes. The supernatant was
used as nuclear fractions.Immunostaining and H&E staining
Cells plated on cover slips were fixed with 4% paraformal-
dehyde-PBS, and permeabilized with 0.25% Triton X-100
for MYOD, desmin, α-actinin staining. Nonspecific re-
actions were blocked with 3% normal goat serum. Cells
were then incubated with mouse monoclonal anti-MyoD
(BD Bioscience), mouse monoclonal anti-desmin (BD
Bioscience) and mouse monoclonal anti-α-actinin (BD
Bioscience) primary antibodies, at the dilutions recom-
mended by the manufacturer, overnight at 4°C, followed by
incubation with secondary antibodies for one hour at room
temperature. Anti-mouse Alexa Fluor 488-conjugated
secondary antibodies (Invitrogen) and 0.1 μg/ml of DAPI
(Santa Cruz Biotechnology, Inc.) were used for immuno-
fluorescence. Cover slips were mounted on slides using
fluorescent mounting medium (Dako, Carpinteria,
CA, USA).
Muscle tissues were fixed with 4% paraformaldehyde-PBS
for 30 minutes at 4°C. The tissues were cryostat sectioned
(10 μm thick) and permeabilized with PBS containing
0.25% Triton X-100 for five minutes. The sections were
then blocked with 3% normal goat serum in PBS, and
incubated rabbit polyclonal anti-dystrophin (Abcam,
Cambridge, UK) at 1:50 to 1:100 dilutions overnight at
4°C. The tissue sections were washed with PBS and then
incubated with TRITC-conjugated anti-rabbit immuno-
globulin G (IgG) antibodies (Sigma-Aldrich) at a 1:500
dilution for one hour at room temperature. The sections
were washed with PBS and mounted with fluorescent
medium (Dako) with DAPI. Immunofluorescence was vi-
sualized using an LSM 5 fluorescence microscope (Zeiss,
Jena, Germany).
For hematoxylin/eosin (H&E) staining, the muscle sam-
ples were fixed with 4% paraformaldehyde-PBS at 4°C for
two days. The tissues were embedded with paraffin and
sectioned with 5 μm thickness. The sections were stained
with H&E staining using a standard protocol.
Human AFS cells transplantation in mice
All animal experiments were performed under the guidance
of the Institutional Ethics Committee of Kyungpook
National University. Immunodeficient BALB/cSlc-nu mice
were maintained under conventional housing conditions
using a chamber system. Male mice aged 12 weeks were
used. hAFS cells at passage 11 were used for in vivo injec-
tion. Before injection, hAFS cells were transduced with
eGFP-lentivirus, and then eGFP-positive hAFS cells were
sorted by fluorescence activated cell sorting (FACS). The
eGFP-positive hAFS cells were cultured for three days and
transduced again with empty vector- or MYOD-lentivirus.
The cells were trypsinized with 0.25% trypsin/EDTA
(Invitrogen) and washed with DPBS (Wellgene, Daegu,
Korea). MYOD transduced hAFS cells were injected
into the left tibialis anterior (TA) muscles of mice two
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infection was confirmed with Western blot using MYOD
antibody (Ab) as well as eGFP transduction rate. The
transduction rate was approximately 80% of infected hAFS
cells. BALB/cSlc-nu mice were anesthetized with intra-
muscular injection of 80 μl of a solution (33.8% Zoletil and
6.5% Rompun in PBS). At the point of transplantation, the
left TA muscle was injected with 40 μl of 10 μM cardio-
toxin, and approximately 500,000 MYOD- or EV-hAFS
cells were injected using a 300 μl insulin syringe to the
center of the muscle. The mice were euthanized at 7 and
21 days. The TA muscles were cross cryostat sectioned
and stained with H&E and immunofluorescence. To
analyze morphological changes in MYOD-hAFS cell-
injected TA muscle, we examined three mice in each
group. A total of 144 sections per each group (48 per
mouse) were stained with H&E. For immunohistochemistry
(IHC) with dystrophin, forty eight sections from each group
around the center area were used, and the IHC images
of dystrophin were used to calculate an average area of
muscle fibers and percentage of centrally nucleated
myofibers. The average size and percentage of centrally
nucleated muscle fibers were measured with i-solution
image software (Daejeon, Korea).
Results
Characterization of hAFS cells
Human amniocentesis specimens were obtained from
Kyungpook National University Hospital. hAFS cells were
isolated as described in the Methods section. In order
to characterize the cells derived from amniotic fluid,
we first analyzed immunophenotypes and gene expression
profiles. RT-PCR analysis showed that hAFS cells express
stem cell marker genes for SCF, GATA-4, VIM, CK18,
OCT4 and FGF5 throughout the culture period (Figure 1a).
These results demonstrate that cells isolated from amni-
otic fluid have typical expression patterns of hAFS cells
[26]. In addition, we also analyzed cell surface markers
of MSCs (CD44, CD73, CD90, and CD105) and major
histocompatibility (MHC) antigens (HLA-ABC and HLA-
DR) in isolated hAFS cells. The results showed strong
expression of CD44, CD73 and CD105, and CD45 and
HLA-DR were negative for these cells (Figure 1b). Expres-
sion of stem cell markers was maintained during the cul-
ture period up to passage 14 (Figure 1b and c). Collectively,
these results suggest that hAFS cells express many
stem cell-associated markers and those markers are well
maintained during ex vivo expansion.
Formation of myotube-like cells by MYOD transduction
To induce myogenic differentiation of hAFS cells, MYOD
lentivirus was constructed and transduced into hAFS cells.
An empty lentiviral vector (EV) was used as a negative
control. Two days after viral transduction, hAFS cellstransduced with MYOD lentivirus expressed significant
amount of MYOD (MYOD-hAFS cells), while no MYOD
expression was detected in empty vector transduced cells
(EV-hAFS cells) (Figure 2a). MYOD-hAFS cells grew
more slowly than EV-hAFS cells. The doubling time of
MYOD-hAFS cells was nearly twofold longer than that of
EV-hAFS cells in the myogenic media (data not shown). A
longer doubling time suggests that MYOD-hAFS cells
undergo myogenic differentiation because growth arrest is
a prerequisite for cellular differentiation [18].
MYOD viral transduction induced morphological changes
of hAFS cells into spindle shape from day 3. At day 10,
a number of multinucleated myotube-like cells was ob-
served. In contrast, no such myotube-like cells were
observed in EV-hAFS cells (Figure 2a). The nuclei were
crowded at both the center and the periphery in a multi-
nucleated myotube-like cell. To confirm myogenic differ-
entiation, we also examined myogenic marker expression
in MYOD-hAFS cells during myogenic differentiation.
Total RNA was collected on days 1, 3, and 7, and mRNA
expression ofMYOG, MYH, MEF2C and DES was analyzed
using RT-PCR. MEF2C which activates myogenic transcrip-
tion in complex with MYOD [27,28], was not enhanced by
MYOD (Figure 2b). Desmin is expressed from an early
stage of skeletal myogenesis [29-31]. Consistently, in hAFS
cells transduced with MYOD-lentivirus, DES was expressed
from day 1, peaked at day 3 and maintained up to day
7 (Figure 2b), suggesting that hAFS cells undergo skeletal
myogenic differentiation by MYOD. MYOG, a gene
expressed in the middle stage of skeletal myogenic de-
velopment, is also expressed by MYOD from day 3 and
the expression is increased up to day 7. MYH, a marker
gene that distinguishes myogenic and non-myogenic
differentiation, is also expressed at days 3 and 7 in
MYOD-hAFS cells [32]. The results demonstrate that
the expression of myogenic marker is consistent with
morphological changes of hAFS cells into myotube-like
cells by MYOD transduction.
MYOD-hAFS cells express pre-myogenic and
myogenic markers
To determine which pre-myogenic mesoderm factors can
mediate myogenesis of hAFS cells expressing MYOD,
RT-PCR was performed with total RNA collected on
days 1, 3 and 7. Pre-myogenic mesoderm factors such
as MEOX1, PAX7, SIX1 and EYA2 are expressed in the
paraxial mesoderm and developing somite of the embryo
[33]. PAX3 is temporarily expressed during an early prolif-
eration period of myogenic progenitors [34,35], whereas
PAX7 is expressed in non-proliferating and undifferentiated
cells, and down-regulates MYOD [36]. In MYOD-hAFS
cells, PAX3 was up-regulated by MYOD at day 1 and then
decreased until day 7 (Figure 2c). However, PAX7 was not
detected in MYOD-hAFS cells (data not shown). These
Figure 1 Expression and immunotyping of stem cell markers in hAFS cells using RT-PCR and flow cytometry. (a) RT-PCR analysis showed
that expression of various stem cell markers was sustained over the population doublings. (b) hAFS cells expressed high levels of mesenchymal
stem cell markers, including CD44, CD90, CD73 and CD105; however, they did not express HLA-DR and CD45 at passages 7 and 11. (c) FACS plots
for MSC markers of (b). hAFS, human amniotic fluid stem; MSC, mesenchymal stem cells.
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induced myogenesis. In addition, the genes involved in
limb muscle development (Meox1) [37], and PAX3 up-
regulation (Six1 and Eya2) [38] were also up-regulated in
MYOD transduced hAFS cells, compared to EV transduced
cells (Figure 2c). MYOD induced expression of SIX1,
MEOX1 and EYA2 at specific time periods. SIX1 gene
was decreased at day 1, but induced at day 3 by MYOD.
MEOX1 gene was induced very early on day 1 by MYOD.
EYA2 expression was induced by MYOD throughout
the differentiation period. Expression of GLI2, FOXC1
and FOXC2, which are involved in muscle deficiency
[37,39-44], was not regulated by MYOD transduction
(Figure 2c). Thus, in hAFS cells, MYOD transduction
induced up-regulation of pre-myogenic mesoderm factors,
such as PAX3, MEOX1, SIX1 and EYA2, prior to up-
regulation of myoblast marker gene expression.
To determine whether the protein levels are correlated
with gene expression and morphological myogenic differ-
entiation, western blot analysis was performed with anti-
MYF5, -myogenin, -desmin, -dystrophin, and -MYOD
antibodies on total protein extracted on days 1, 3, 7, and
10. As expected, MYOD protein was induced from day 1and peaked at days 3 and 7 in MYOD-hAFS cells, but little
was expressed in EV-hAFS cells (Figure 2d). MYF5 ex-
pression was not changed by MYOD transduction during
myogenesis, whereas desmin was strongly expressed from
day 3 (Figure 2d). Dystrophin, a major component of
the dystrophin–glycoprotein complex in muscle fibers,
responsible for the maintenance of sarcolemma integrity
[45], was also expressed from day 3. Because desmin is an
early marker of skeletal myogenic lineage differentiation
and is expressed in myogenic committed-mononucleated
cells before fusion [46], hAFS cells transduced with MYOD
are differentiated into skeletal myoblasts.
Intracellular localization of myogenic proteins and
phosphorylation/dephosphorylation of MYOD in hAFS cells
To further confirm myogenic differentiation of hAFS cells
by MYOD transduction, we examined intracellular loca-
lization of MYOD and myogenesis-related proteins. As
expected, over-expressed MYOD was predominantly local-
ized in the nucleus, suggesting that they are actively in-
volved in expression of myogenesis-associated genes. In
addition, desmin was also induced by MYOD transduction
and localized in the cytoplasm of hAFS cells. α-Actinin, a
Figure 2 Transduction of MYOD and EV lentiviruses to hAFS cells. (a) MYOD mRNA expression in hAFS cells infected with empty or MYOD
lentivirus was analyzed. Morphology of hAFS cells infected with EV lentivirus at day 3 and MYOD lentivirus at days 3 and 10 is shown. Myotube-like
morphology was clearly detected in hAFS cells transduced with MYOD at day 10. (b) and (c) mRNA expression of myogenic genes. hAFS cells were
cultured for one, three, and seven days in myogenic differentiation medium. (b) Myogenic marker genes were analyzed using RT-PCR. (c) Expression
of pre-myogenic marker genes was analyzed. (d) Levels of myogenic proteins during myogenic differentiation of hAFS cells. hAFS cells differentiated
for one, three, seven and ten days in myogenic medium. The protein levels were analyzed with antibodies specific to each myogenic protein
(Scale bar = 20 μm). EV, empty vector; hAFS, human amniotic fluid stem.
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only in myotubes (Figure 3a). These results suggest that
MYOD transduction induces sufficient myogenic differen-
tiation to the terminal stage for formation of myotubes.
To determine whether phosphorylation of MYOD is
associated with myogenic differentiation of hAFS cells,
the cells were transduced with FLAG tagged MYOD
lentivirus. (Figure 3b) The cell pellet was fractionated
into cytosol and nuclear fractions, as described in the
Methods section, and each fraction was confirmed using
nuclear specific SP1 protein and cytosol specific GAPDH
protein. MYOD was expressed mainly as 47 kDa (phos-
phorylated form) [18] from day 1. At day 3, both phosphor-
ylated and dephosphorylated MYOD reached their highest
levels; however, phosphorylated MYOD was dominant over
the dephosphorylated one (Figure 3b and c). Of particular
interest, MYOD-hAFS cells started to fuse with one
another from day 3 and the highest expression of MYOD
was observed during this time period. The level of
phosphorylated and dephosphorylated MYOD was also
increased. These results suggest that an increase of
phosphorylated and dephosphorylated MYOD in the nu-
cleus may contribute to the formation of multi-nucleated
myotube.The contribution of hAFS cells to regeneration of skeletal
muscle injury in vivo
Having established that MYOD transduction in hAFS
cells induces differentiation to skeletal myotubes, we next
asked whether MYOD-expressing hAFS cells contribute
or enhance myogenic regeneration after in vivo trans-
plantation. To label hAFS cells, EGFP lentiviruses were
transduced to hAFS cells, and eGFP-positive cells were
isolated with FACS Aria (93.82% positive; Additional
file 1: Figure S1). EGFP-positive hAFS cells were cultured
for three days and transduced again with MYOD- or EV-
lentiviruses. hAFS cells transduced twice with eGFP and
MYOD or empty viruses were able to differentiate into
myoblasts (data not shown). Transduction efficiency
was measured with eGFP lentivirus (about 80%; Additional
file 2: Figure S2). Transduction of MYOD lentivirus
was confirmed with Western blot with MyoD antibody
(Figure 2d). These eGFP-positive MYOD-expressing or
eGFP-positive EV-expressing hAFS cells were co-injected
with cardiotoxin (CTX) into TA muscles of immunodefi-
cient mice (n = 3) [18,47]. CTX was injected to induce
injury in the TA muscle [48]. After 7 and 21 days, the mice
were sacrificed, and tissues were sectioned (5 μm) and
stained with H&E. A total of 144 sections of each group
Figure 3 Intracellular localization of MYOD, desmin and α-actinin
proteins during myogenesis. (a) Immunocytochemistry of hAFS cells
infected with MYOD lentivirus. The infected cells were cultured in
myogenic differentiation medium for seven days. Myogenic marker
proteins, MYOD, desmin and α-actinin were immunostained with
monoclonal antibodies and Alexa Fluor 488 conjugated secondary
antibody (upper). Nuclei were stained with DAPI (lower). (b) Western
blotting of MYOD protein in the nuclear-cytosol fractions of differentiating
hAFS cells at 1, 3 and 7 days. hAFS cells were transduced with FLAG
pHJ-1 (FLAG) or MYOD-FLAG pHJ-1 (MYOD-FLAG). Phosphorylated
MYOD (black arrow head, 47 KDa) and dephosphorylated MYOD
(white arrow head, 45 KDa) are indicated. (c) The ratio of phosphorylated
and dephosphorylated MYOD during myogenic differentiation. The band
densities of Flag tagged MYOD at (b) were measured and the densities
were calculated as phosphorylated/dephosphorylated MYOD
(Scale bar = 10 μm). DAPI, 4',6-diamidino-2-phenylindole; hAFS,
human amniotic fluid stem.
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groups) were stained with H&E. Seven days after cell
transplantation, no significant difference was observed
among control, EV-, and MYOD-hAFS cell groups
(Figure 4a). However, at 21 days after injection, muscle
volume of the MYOD-hAFS cell-injected group was
increased, compared to those of the control or EV-hAFS
cell group (Figure 4a). At 21 days post injection, consistent
with increased muscle volume, the muscle fiber area of
MYOD-hAFS cell-transplanted TA muscle was largerthan that of CTX only or EV-hAFS cell-injected TA
muscles (n = 9) (Figure 4b). Forty eight sections in each
group around the center area were used for immunofluor-
escence with dystrophin. The IHC images of dystrophin
were used to calculate an average size of muscle fibers.
IHC staining with dystrophin antibody also showed that
muscle fibers of MYOD-hAFS cell-transplanted TA were
larger than those of CTX only or EV-hAFS cell-injected
TA muscles (Figure 4c). Histomorphometric analysis
showed that the average size (μm2) of centrally nucleated
myofiber was 947.9 ± 108.1 (control), 992.7 ± 85.7 (EV)
and 1,467.9 ± 124.0 (MYOD) (CON:MYOD *P <0.004).
These results suggest increased size of muscle fibers
injected with MYOD-hAFS cells. The average size of whole
myofibers was 762.3 ± 191.7 (control), 820.1 ± 141.4 (EV),
and 992.5 ± 188.2 (MYOD) (CON:MYOD **P <0.03). Simi-
larly, muscle fibers injected with MYOD-hAFS cells showed
an increase in size. Because the average size of normal
myofibers in the TA muscle (no CTX) was 1,072.0 ± 77.3,
increased size (992.5 ± 188.2) of myofibers by MYOD-hAFS
cells may not mean hypertrophy. It seems rather to be
normal growth of myofibers during regeneration. In
addition, the percentage of centrally nucleated fibers
(regeneration index) was 65.2% (control, 1,020/1,564),
50.8% (EV, 740/1,457) and 42.9% (MYOD, 595/1,386)
(CON:MYOD *P <0.02). These results show that MYOD-
hAFS cells injected TA muscle undergo an active regener-
ation (Figure 4c).
We also asked the question whether injected hAFS cells
become a direct part of the myofiber or secrete some
growth factors to induce formation of large myofibers.
EGFP labeled EV- or MYOD-hAFS cells were injected
into TA muscles. After 21 days, the muscle tissues were
cryostat sectioned and observed under fluorescence mi-
croscopy. As shown in Figure 4d, the injected cells were
clustered, but did not become part of the myofiber. These
results suggest that hAFS cells expressing MYOD may
induce large myofibers through paracrine action of some
growth factors.
To examine the question of whether muscles regenerated
by MYOD-hAFS cells are functional, cryostat sections
were stained with Alexa-594 conjugated α-bungarotoxin
(a-BTX). a-BTX allows for the detection of the distribution
of acetylcholine receptor, which is confined to the post-
synaptic membrane of the neuromuscular junction [13].
a-BTX positive signal was more frequently and strongly
detected in MYOD-hAFS cell-injected TA muscles than
control and EV-hAFS cell-injected muscles (Figure 4e). For
quantification, the a-BTX-bound area was measured using
i-solution image software. The a-BTX-bound area was
selected in the same location of five muscle slides showing
the same position (each slide had eight TA muscle sections)
and used for calculation of the average bounded area.
The results showed that the a-BTX bound area in
Figure 4 Regeneration of TA muscle injury by MYOD transduced hAFS cells. Left TA muscle of immunodeficient BALB/cSlc-nu mice was
injured with cardiotoxin (0.4 nM/mouse), and EGFP positive hAFS cells transduced with EV and MYOD viruses. (a) H&E staining of TA muscles at 7
and 21 days after injection of EV- or MYOD-hAFS cells (black dashed line: injured site). (b) The area of muscle tissue was measured using the
i-solution image program at 7 and 21 days after injection (n = 9; three per mouse). The muscle area was significantly increased in the MYOD-hAFS
cell-injected group compared to the group injected with EV-hAFS cells or the control (*P <0.0002 and **P <0.002). (c) The size of muscle fibers of
MYOD-hAFS cell-transplanted TA muscle was larger than that of CTX only or EV-hAFS cell injected TA muscles. Using the i-solution program, the
average size of centrally nucleated myofibers and whole myofibers was calculated (n = 48; 16 per mouse) (*P < .004 and **P <0.03). The percentage of
centrally nucleated fibers over total fibers was also calculated (n = 48; 16 per mouse) (*P <0.02). (d) Injected hAFS cells were visualized with eGFP signal
(green) and DAPI with confocal microscopy (white dashed line: regenerating muscle fiber). (e) TA muscles injected with CTX only (control), EV- or
MYOD-hAFS cells were stained with α-BTX at 21 days after injection. The area of α-BTX binding was measured using the i-solution image program
(n = 32; 16 per mouse) (*P <0.03 and **P <0.02) (Scale bar; a = 500 μm, 7 days of c = 10 μm and others = 20 μm). α-BTX, α-bungarotoxin; CTX,
cardiotoxin; DAPI, 4',6-diamidino-2-phenylindole; EV, empty vector; hAFS, human amniotic fluid stem; TA, tibialis anterior.
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than that of the control, and 1.31 fold higher than that of
the EV-hAFS cell injected muscle (Figure 4e). These results
suggest that the neuromuscular junction of MYOD-hAFS
cell injected muscle is regenerated.Discussion
Myogenic differentiation of hAFS cells can be induced by
5′-azacytidine (5′-AZA) in myogenic medium. 5′-AZA-
stimulated hAFS cells express MYOD and some myogenic
factors [7]. We also tested myogenic differentiation with
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induced an early myoblast differentiation, but not myotube
formation (data not shown). These results suggest that
genetic reprogramming by DNMT inhibitor is not suffi-
cient for induction of terminal myogenic differentiation
of hAFS cells. On the other hand, expression of MYOD
induces substantial myogenic differentiation of cells [49].
Consistent with these reports, forced expression of MYOD
in hAFS cells also induced myogenic differentiation
(Figure 2a and b). Results of myogenic marker analysis
showed that late myogenic markers such as myogenin,
MyHC and dystrophin were induced by forced expression
of MYOD (Figure 2b), indicating that hAFS cells expressing
MYOD can differentiate up to the late stage of myogenesis.
Muscle development is regulated by distinct molecular
mechanisms. In extraocular, tongue and laryngeal muscles,
and branchial arches, pituitary homeobox 2 predominantly
controls the myogenic hierarchy, leading to up-regulation
of MYF5 and MYOD, and, eventually, terminal differenti-
ation induced by myogenin. In contrast, in limb muscles,
SIX1 and EYA2 proteins regulate PAX3, which in turn
controls proliferative myogenic cells [50]. Differentiation
of myogenic cells is induced by a cascade involving MYF5,
MRF4, MYOD and myogenin. In trunk muscles, MYF5
or MRF4 can exhibit parallel activation of MYOD and
myogenin, whereas PAX3 acts upstream of MYOD [25].
Because forced expression of MYOD induced expression
of pre-myogenic genes such as PAX3, SIX1, MEOX1 and
EYA2, myogenic differentiation of hAFS cells appears to
occur through a mechanism similar to that of limb muscle
development. These results suggest that MYOD directly
or indirectly regulates expression of the pre-myogenic and
myogenic genes. Recently Akizawa et al. showed that
amnion-derived cells can be differentiated into myoblast
[51]. We further examined in hAFS cells, MYOD lentivirus
stimulated pre-myogenic and myogenic genes, and we also
demonstrated regeneration of chemically injured muscle
by MYOD expressing hAFS cells.
Transcriptional activity of MYOD is regulated by phos-
phorylation and dephosphorylation [16-19]. Over-expressed
MYOD in hAFS cells was predominantly localized in the
nucleus (Figure 3a and b), suggesting that they are actively
involved in expression of myogenesis-associated genes.
Analysis of the phosphorylation status of MYOD showed
that the phosphorylated form of MYOD was dominantly
detected at day 3, the time when fusion of hAFS cells
starts to occur (Figure 3b and c). This is interesting
because dephosphorylated MYOD causes cell fusion under
conditions of high mitogenesis [17] and phosphorylation
of Thr115 of MYOD negatively regulates mouse myoblast
differentiation [25] through inhibition of the DNA binding
activity of the MYOD homodimer [16]. Therefore, de-
phosphorylated MYOD may positively regulate myogenic
differentiation.However, during enhanced myogenic differentiation
of hAFS cells by forced expression of MYOD, MYOD
became highly phosphorylated at day 3 (Figure 3b). This
appears to be contrary to previous reports [16,17,25].
However, MYOD overexpression induced an increase
of both phosphorylated and dephosphorylated MYOD,
and, thus, a relative amount of dephosphorylated MYOD
was also increased, compared to control (Figure 3b).
Therefore, an increase in the amount of dephosphorylated
MYOD, rather than the phosphorylation/dephosphoryla-
tion ratio, may participate in myogenic transcription in
hAFS cells expressing MYOD. Another possibility is
that phosphorylated MYOD may form a heterodimer
with other factors, such as E12 [16], and regulate myogenic
differentiation.
Evaluation of the myogenic effect of forced MYOD
expression in vivo is needed for determination of its
effect n muscle regeneration. A previous study using
hAFS cells reported that transplantation of unstimu-
lated hAFS cells into injured TA muscle had no detect-
able effect on regeneration [12,52], although hAFS cells
show an immunomodulatory effect [53] and recruit
host progenitor cells that help in the regeneration of
the injured region [54]. In this report, we transplanted
hAFS cells overexpressing MYOD into injured TA
muscle, and found that muscle volume and myofiber
size were increased by hAFS cells expressing MYOD
(Figure 4). The increased muscle volume appears to be
due to increased myofiber size; however, increased size
of myofiber did not look like hypertrophy. Because a
significantly large number of hAFS cells were trans-
planted, we can assume that the injected cells differen-
tiate and fuse with host myoblasts. This is the case
in MSCs, showing that MYOD transduced MSCs fuse
with myoblasts to form the terminal differentiated
myofiber within eight to twelve weeks in a dog [55].
However, injected hAFS cells were maintained and
clustered within muscle tissues and did not fuse with
host myofiber at 21 days after transplantation (Figure 4d).
This may be because injected hAFS cells did not have
sufficient time to fuse with host muscle fiber. Of
particular interest, even though transplanted hAFS cells
did not fuse with host myofiber, hAFS cells expressing
MYOD contribute significantly to the increased size of
myofibers. Therefore, paracrine action of hAFS cells
expressing MYOD may contribute to the increased size
of myofibers. In addition, the paracrine factor may also
regulate formation of the neuromuscular junction. Devel-
opment of neuromuscular junction represents muscle
functionality and this may also contribute to the increased
size of myofibers. Currently, the nature of paracrine
factor released from hAFS cells expressing MYOD is
not known. However, it may control regeneration of
myofiber.
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In conclusion, hAFS cells were shown to be effectively
differentiated to myogenic lineage by the transduced
MYOD. The underlying mechanism includes expression
of pre-myogenic factors followed by myogenic proteins,
leading to skeletal myogenesis. Subsequent in vivo study
showed that MYOD-expressing hAFS cells enhance
the size of myofibers, however, they do not fuse with
host myofiber, indicating paracrine induction of myofiber
formation. Thus, genetic modification and optimization of
hAFS cells may provide a useful alternative tool for regen-
eration of damaged muscle, even dystrophic muscles.
Additional files
Additional file 1: Figure S1. Confirmation of EGFP positive human AFS
cells. Three to five days after eGFP lentivirus transduction, cells were
trypsinized and analyzed with FACS. The results showed that 93.82% of
the cells were positive for GFP.
Additional file 2: Figure S2. Transduction efficiency of lentivirus. To
examine lentivirus transduction efficiency, EGFP lentivirus was transduced
to hAFS cells. After three days of culture, fluorescent cells were counted
using i-solution program. The results showed that transduction efficiency
of 1/2 diluted eGFP lentiviruses was about 80% (Scale bar = 10 μm).
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